Pharming Group N.V. or Bausch Health Companies Inc.: Who Invests More in Innovation?

Bausch vs. Pharming: A Decade of R&D Investment

__timestampBausch Health Companies Inc.Pharming Group N.V.
Wednesday, January 1, 201424600000014182353
Thursday, January 1, 201558280000015503028
Friday, January 1, 201645500000016183585
Sunday, January 1, 201736600000022382849
Monday, January 1, 201841400000033038206
Tuesday, January 1, 201947100000031777040
Wednesday, January 1, 202045200000041464134
Friday, January 1, 202146500000067178053
Saturday, January 1, 202252900000052531000
Sunday, January 1, 202360400000068914000
Loading chart...

Unleashing insights

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Bausch Health Companies Inc. and Pharming Group N.V. have shown contrasting approaches to research and development (R&D) investments. From 2014 to 2023, Bausch Health consistently outspent Pharming Group, with an average annual R&D expenditure nearly 13 times higher. In 2023, Bausch Health's R&D expenses peaked at approximately $604 million, marking a 145% increase from 2014. Meanwhile, Pharming Group's investment grew by nearly 386%, reaching around $69 million in 2023. This disparity highlights Bausch Health's robust commitment to innovation, while Pharming Group's rapid growth in R&D spending signals its rising ambition. As the pharmaceutical landscape evolves, these investment strategies will play a crucial role in shaping the future of healthcare solutions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025